CN Patent

CN117337305A — 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制

Assigned to AstraZeneca AB · Expires 2024-01-02 · 2y expired

What this patent protects

本公开涉及用于治疗系统性红斑狼疮(SLE)的方法和组合物。

USPTO Abstract

本公开涉及用于治疗系统性红斑狼疮(SLE)的方法和组合物。

Drugs covered by this patent

Patent Metadata

Patent number: CN117337305A
Jurisdiction: CN
Classification: —
Expires: 2024-01-02
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.